| Symbol | IMMX |
|---|---|
| Name | IMMIX BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11400 WEST OLYMPIC BOULEVARD,SUITE 200, LOS ANGELES, California, 90064, United States |
| Telephone | +1 310 651-8041 |
| Fax | — |
| — | |
| Website | https://www.immixbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001873835 |
| Description | Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Immix Biopharma, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001274173-26-000146 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Immix Biopharma, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001104659-26-054945 <b>Size:</b> 15 KB
Read moreImmix Biopharma to Participate in the Jefferies Global Healthcare Conference
Read moreImmix Biopharma to Participate in the Jefferies Global Healthcare Conference
Read moreNew Form ARS - Immix Biopharma, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001493152-26-015324 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Immix Biopharma, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001493152-26-015322 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Immix Biopharma, Inc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001493152-26-015320 <b>Size:</b> 2 MB
Read more(80% Positive) IMMIX BIOPHARMA, INC. (IMMX) Announces Enrollment Update for expected Due to Patient Enrollment Issues
Read moreImmix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Read moreImmix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06097832 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Phase1 | Light Chain (AL) Amyloidosis | Recruiting | 2024-06-05 | 2039-01-01 | ClinicalTrials.gov |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Sol… | Phase1 | Advanced Solid Tumor | Unknown | 2023-02-03 | 2024-01-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| IMX-110 combined with Tislelizumab | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05840835 |
| NXC-201 CAR-T | Other | Phase PHASE1 | Light Chain (AL) Amyloidosis | RECRUITING | NCT06097832 |
| NXC-201 CAR-T | BIOLOGICAL | Phase PHASE1 | Light Chain (AL) Amyloidosis | RECRUITING | NCT06097832 |
| IMX-110 combined with Tislelizumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05840835 |